Skip Navigation

Nucleic Acids Symposium Series 2008 52(1):15; doi:10.1093/nass/nrn008
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Cantor, C. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Cantor, C. R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2008 Oxford University Press

This article appears in the following Nucleic Acid Symposium Series issue: Joint Symposium of the 18th International Roundtable on Nucleosides, Nucleotides and Nucleic Acids and the 35th International Symposium on Nucleic Acids Chemistry [View the issue table of contents]

Quantitative, Sensitive Analysis of DNA and RNA

Charles R. Cantor*

SEQUENOM, Inc. San Diego, CA USA

*Corresponding Authors; E-mail: ccantor{at}sequenom.com

Abstract

DNA or RNA sequences that contain useful information about disease risk, disease occurrence, therapeutic response, and probable prognosis are potentially valuable biomarkers. They can be accessed by biopsy, or in ideal cases non-invasively from easily accessible fluids like blood or urine. Tolls are available for biomarker discovery, validation, and clinical use. Discovery usually requires whole genome analysis, and currently this is done with either nucleic acid arrays (DNA chips) or sequencing. Validation requires high quality data scalability to large numbers of samples. Clinical utility normally needs a high degree of automation, and for non-invasive approaches, great experimental sensitivity and specificity but on small numbers of samples.

No one platform can efficiently span the broad range of requirements and project sizes. SEQUENOM uses an automated mass spectrometry platform for the quantitative analysis of DNA and RNA in a variety of settings including genotyping, genecopy number measurements, gene expression, epigenetics, and automated bacterial and viral identification.

In collaboration with Amit Meller at Boston University, SEQUENOM is developing optically detected nanospores as a companion platform for its mass spectrometry offering. Both platform use similar homogeneous solution biochemistry to prepare samples. Both platforms depend on vary rapid digital signal processing for real time data analysis and interpretation. The nanopore method uses pores large enough to pass single-stranded DNA but too small to pass double strands. Hence pore passage strips off one of the DNA stands, and optical method are used to detect changes in fluorophores on this strand or attached to reporter probes, as it is stripped. We expect that, when mature, the nanopore method will be extremely const effective for whole genome analysis of genotypes, gene expression, epigenetics, and whole genome sequencing. A key aspect of the nanopore method is its speed. Post sample preparation, many analyses may require only seconds of instrument time.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.